Back to Search
Start Over
AB0251 Early Onset of Benefit by Patient-Reported Outcomes (PROs) with Sarilumab Treatment in RA
- Source :
- Annals of the Rheumatic Diseases. 75:984.2-985
- Publication Year :
- 2016
- Publisher :
- BMJ, 2016.
-
Abstract
- Background Efficacy, including improvements in patient-reported outcomes (PROs), was demonstrated in 2 phase 3 trials, MOBILITY 1 (NCT01061736) and TARGET 2 (NCT01709578), of sarilumab, an investigational human anti–interleukin 6 receptor monoclonal antibody. The most common treatment-emergent adverse events in both studies were infections, neutropenia, injection site reactions, and increased transaminases. Objectives To evaluate the early onset of benefit of sarilumab treatment measured by PROs. Methods In both studies, adults with moderate-to-severe, active rheumatoid arthritis (RA) were randomized to 1 of 3 groups receiving placebo, sarilumab 150 mg, or sarilumab 200 mg subcutaneously (SC) every 2 weeks (q2w) plus methotrexate (MTX; MOBILITY) or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; TARGET). PROs assessed as early as week 2 included patient global assessment of disease activity (PtGA), pain assessed by visual analog scale (VAS), Health Assessment Questionnaire–Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), sleep by VAS (MOBILITY), and AM stiffness by VAS (TARGET). Changes from baseline were analyzed using mixed-model repeated measures with region, number of prior tumor necrosis factor inhibitors (TNFis) (TARGET) or prior biologic use (MOBILITY), visit, treatment, treatment-by-visit interaction, and baseline PRO scores as covariates. Results Greater improvements were reported by patients treated with sarilumab 150 and 200 mg SC q2w vs placebo as early as week 2 in PtGA, pain VAS, HAQ-DI, FACIT-F, sleep VAS, and AM stiffness VAS (nominal P Conclusions Sarilumab treatment rapidly improved a broad range of PROs in patients with RA with inadequate response to MTX (MOBILITY) or TNFis (TARGET); these improvements were observed as early week 2 and maintained through week 24. The results demonstrate the early benefit of sarilumab treatment based on patients9 own assessments of their disease. References Genovese et al. Arthritis Rheumatol. 2015;67:1424–1437. Fleischmann et al. Arthritis Rheumatol. 2015;67(suppl 10). Acknowledgement This study was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Disclosure of Interest V. Strand Consultant for: AbbVie, Amgen, AstraZeneca, Biogen, BMS, Celgene, Celltrion, Consortium of Rheumatology Researchers of North America (CORRONA), Crescendo/Myriad Genetics, EMD Serono, Genentech/Roche, GSK, Janssen, Eli Lilly, Novartis, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Sandoz, Sanofi, and UCB, C. Chen Shareholder of: Regeneron Pharmaceuticals, Inc, Employee of: Regeneron Pharmaceuticals, Inc, P. Mahajan Shareholder of: Sanofi, Employee of: Sanofi, M. Kosinski Consultant for: Sanofi and Regeneron, E. Mangan Shareholder of: in Pfizer Inc and Regeneron Pharmaceuticals, Inc, Employee of: Regeneron Pharmaceuticals, Inc, H. van Hoogstraten Shareholder of: Sanofi, Employee of: Sanofi, N. Graham Shareholder of: Regeneron Pharmaceuticals, Inc, Employee of: Regeneron Pharmaceuticals, Inc, Y. Lin Shareholder of: Sanofi, Employee of: Sanofi, E. Keystone Consultant for: has consulting agreements/advisory board membership with Abbott, AstraZeneca, Biotest, BMS, F. Hoffman-La Roche, Genentech, Janssen, Eli Lilly, Merck, Pfizer Inc, and UCB; and has speaker honoraria agreements with Abbott, Amgen, AstraZeneca, BMS Canada, F. Hoffman-La Roche, Janssen, Pfizer Inc, and UCB., J. Braun Grant/research support from: received honoraria for talks, advisory boards, paid consultancies, and grants for studies from AbbVie (Abbott), Amgen, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Hospira, Janssen, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer Inc (Wyeth), Roche, Sanofi-Aventis, and UCB, Consultant for: received honoraria for talks, advisory boards, paid consultancies, and grants for studies from AbbVie (Abbott), Amgen, Biogen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Hospira, Janssen, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer Inc (Wyeth), Roche, Sanofi-Aventis, and UCB
- Subjects :
- medicine.medical_specialty
business.industry
Immunology
General Biochemistry, Genetics and Molecular Biology
Disease activity
03 medical and health sciences
Sarilumab
0302 clinical medicine
Rheumatology
030220 oncology & carcinogenesis
Increased transaminases
Internal medicine
Injection site
Immunology and Allergy
Medicine
In patient
business
Antirheumatic drugs
030217 neurology & neurosurgery
Early onset
Subjects
Details
- ISSN :
- 14682060 and 00034967
- Volume :
- 75
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi...........3e2dad83e9db6116258e7a47b06fc22f
- Full Text :
- https://doi.org/10.1136/annrheumdis-2016-eular.4214